PLoS ONE (Jan 2024)

Efficacy of pegylated Graphene oxide quantum dots as a nanoconjugate sustained release metformin delivery system in in vitro insulin resistance model.

  • Kunal Sarkar,
  • Arindam Chatterjee,
  • Biswabandhu Bankura,
  • Sarbashri Bank,
  • Nirvika Paul,
  • Srilagna Chatterjee,
  • Anwesha Das,
  • Koushik Dutta,
  • Santanu Chakraborty,
  • Sriparna De,
  • Alaa A Al-Masud,
  • Gausal Azam Khan,
  • Dipankar Chattopadhyay,
  • Madhusudan Das

DOI
https://doi.org/10.1371/journal.pone.0307166
Journal volume & issue
Vol. 19, no. 8
p. e0307166

Abstract

Read online

Metformin, the primary therapy for type 2 diabetes mellitus (T2DM), showed limitations such as varying absorption, rapid system clearance, required large amount, resistance, longstanding side effects. Use of Nano formulations for pharmaceuticals is emerging as a viable technique to reduce negative consequences of drug, while simultaneously attaining precise release and targeted distribution. This study developed a Polyethylene Glycol conjugated Graphene Oxide Quantum dots (GOQD-PEG) nanocomposite for the sustained release of metformin. Herein, we evaluated the effectiveness of metformin-loaded nanoconjugate in in vitro insulin resistance model. Results demonstrated drug loaded nanoconjugate successfully restored glucose uptake and reversed insulin resistance in in vitro conditions at reduced dosage compared to free metformin.